{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:20:37Z","timestamp":1792120837247,"version":"4.4.0"},"reference-count":67,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5,27]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Double-unit cord blood transplantation (dCBT) has been associated with high rates of progression-free survival (PFS) in adults with hematologic malignancies but also with relatively high rates of acute graft-versus-host disease (aGVHD). We conducted a single-arm, phase 2 clinical trial that investigated the addition of tocilizumab, an interleukin-6 receptor blocker, to cyclosporine-A (CSA) and mycophenolate mofetil (MMF) for aGVHD prophylaxis after intermediate-intensity dCBT. A total of 45 patients (median age, 47 years; range, 27-60 years; 80% acute leukemia; median hematopoietic cell transplant-comorbidity index, 2) were enrolled from March 2018 to March 2021. Transplant outcomes were compared with 39 previous CSA and MMF dCBT controls with similar inclusion criteria. Tocilizumab recipients had less pre-engraftment syndrome (38%; 95% confidence interval [CI], 24-52 vs 72%; 95% CI, 54-84; P &amp;lt; .001) but inferior day 45 neutrophil engraftment (93%; median, 25.5 days vs 97%; median, 22 days; P = .009]. The primary end point of day 100 grade 2 to 4 aGVHD was no different between groups (71%; 95% CI, 55-82 with tocilizumab vs 82%; 95% CI, 65-91; P = .11). However, there was a trend toward a lower day 100 incidence of stage 1 to 4 lower gastrointestinal aGVHD with tocilizumab (16%; 95% CI, 7-28 vs 33%; 95% CI, 19-48; P = .059). There were no significant differences in the 3-year incidences of relapse, transplant-related mortality, PFS, or overall survival between the groups. Tocilizumab recipients exhibited a distinct pattern of gut microbiome disruption. In summary, tocilizumab-based GVHD prophylaxis delayed neutrophil recovery without a significant reduction in aGVHD and had no survival benefit after dCBT. Investigation of alternative strategies to prevent severe aGVHD after dCBT is warranted. This trial was registered at www.clinicaltrials.gov as #NCT03434730.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024014177","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T15:32:09Z","timestamp":1748359929000},"page":"2570-2584","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":4,"title":["Phase 2 trial of cyclosporine-A, mycophenolate mofetil, and tocilizumab GVHD prophylaxis in cord blood transplantation"],"prefix":"10.1182","volume":"9","author":[{"given":"Ioannis","family":"Politikos","sequence":"first","affiliation":[{"name":"1Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"2Department of Medicine, Weill Cornell Medical College, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5352-974X","authenticated-orcid":false,"given":"Samantha","family":"Brown","sequence":"additional","affiliation":[{"name":"3Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua A.","family":"Fein","sequence":"additional","affiliation":[{"name":"2Department of Medicine, Weill Cornell Medical College, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1929-5705","authenticated-orcid":false,"given":"Stephen","family":"Eng","sequence":"additional","affiliation":[{"name":"1Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian","family":"Casem","sequence":"additional","affiliation":[{"name":"1Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6308-9346","authenticated-orcid":false,"given":"Stephanie","family":"Chinapen","sequence":"additional","affiliation":[{"name":"1Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Quach","sequence":"additional","affiliation":[{"name":"1Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2425-1069","authenticated-orcid":false,"given":"Andromachi","family":"Scaradavou","sequence":"additional","affiliation":[{"name":"4Bone Marrow Transplantation Service, Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"5Department of Pediatrics, Weill Cornell Medical College, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Cho","sequence":"additional","affiliation":[{"name":"6Department of Hematology, Hackensack University Medical Center, John Theurer Cancer Center, Hackensack, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0794-3226","authenticated-orcid":false,"given":"Parastoo","family":"Dahi","sequence":"additional","affiliation":[{"name":"1Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"2Department of Medicine, Weill Cornell Medical College, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1944-5053","authenticated-orcid":false,"given":"Sergio A.","family":"Giralt","sequence":"additional","affiliation":[{"name":"1Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"2Department of Medicine, Weill Cornell Medical College, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boglarka","family":"Gyurkocza","sequence":"additional","affiliation":[{"name":"1Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"2Department of Medicine, Weill Cornell Medical College, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan M.","family":"Hanash","sequence":"additional","affiliation":[{"name":"1Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"2Department of Medicine, Weill Cornell Medical College, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann A.","family":"Jakubowski","sequence":"additional","affiliation":[{"name":"1Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"2Department of Medicine, Weill Cornell Medical College, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6066-1861","authenticated-orcid":false,"given":"Esperanza B.","family":"Papadopoulos","sequence":"additional","affiliation":[{"name":"1Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"2Department of Medicine, Weill Cornell Medical College, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5910-4571","authenticated-orcid":false,"given":"Miguel-Angel","family":"Perales","sequence":"additional","affiliation":[{"name":"1Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"2Department of Medicine, Weill Cornell Medical College, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9422-5766","authenticated-orcid":false,"given":"Doris M.","family":"Ponce","sequence":"additional","affiliation":[{"name":"1Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"2Department of Medicine, Weill Cornell Medical College, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian C.","family":"Shaffer","sequence":"additional","affiliation":[{"name":"1Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"2Department of Medicine, Weill Cornell Medical College, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roni","family":"Tamari","sequence":"additional","affiliation":[{"name":"1Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"2Department of Medicine, Weill Cornell Medical College, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0032-6559","authenticated-orcid":false,"given":"James W.","family":"Young","sequence":"additional","affiliation":[{"name":"1Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"2Department of Medicine, Weill Cornell Medical College, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Devlin","sequence":"additional","affiliation":[{"name":"3Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4029-7625","authenticated-orcid":false,"given":"Jonathan U.","family":"Peled","sequence":"additional","affiliation":[{"name":"1Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"2Department of Medicine, Weill Cornell Medical College, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliet N.","family":"Barker","sequence":"additional","affiliation":[{"name":"2Department of Medicine, Weill Cornell Medical College, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,5,27]]},"reference":[{"issue":"15","key":"2025052711320146200_bib1","doi-asserted-by":"crossref","first-page":"3824","DOI":"10.1182\/bloodadvances.2022008572","article-title":"Analysis of disparities in time to allogeneic transplantation in adults with acute myelogenous leukemia","volume":"7","author":"Fingrut","year":"2023","journal-title":"Blood Adv"},{"issue":"7","key":"2025052711320146200_bib2","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1182\/bloodadvances.2018028662","article-title":"Racial disparities in access to HLA-matched unrelated donor transplants: a prospective 1312-patient analysis","volume":"3","author":"Barker","year":"2019","journal-title":"Blood Adv"},{"issue":"11","key":"2025052711320146200_bib3","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/j.bbmt.2010.08.011","article-title":"Availability of cord blood extends allogeneic hematopoietic stem cell transplant access to racial and ethnic minorities","volume":"16","author":"Barker","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"23","key":"2025052711320146200_bib4","doi-asserted-by":"crossref","first-page":"6064","DOI":"10.1182\/bloodadvances.2020003371","article-title":"High progression-free survival after intermediate intensity double unit cord blood transplantation in adults","volume":"4","author":"Barker","year":"2020","journal-title":"Blood Adv"},{"issue":"10","key":"2025052711320146200_bib5","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa1602074","article-title":"Cord-blood transplantation in patients with minimal residual disease","volume":"375","author":"Milano","year":"2016","journal-title":"N Engl J Med"},{"issue":"19","key":"2025052711320146200_bib6","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1182\/blood-2009-05-220525","article-title":"Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units","volume":"114","author":"Verneris","year":"2009","journal-title":"Blood"},{"issue":"11","key":"2025052711320146200_bib7","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1016\/j.bbmt.2015.07.029","article-title":"High disease-free survival with enhanced protection against relapse after double-unit cord blood transplantation when compared with T cell-depleted unrelated donor transplantation in patients with acute leukemia and chronic myelogenous leukemia","volume":"21","author":"Ponce","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2025052711320146200_bib8","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/leu.2016.288","article-title":"Impact of graft-versus-host disease on outcomes after unrelated cord blood transplantation","volume":"31","author":"Kanda","year":"2017","journal-title":"Leukemia"},{"issue":"6","key":"2025052711320146200_bib9","doi-asserted-by":"crossref","first-page":"365.e1","DOI":"10.1016\/j.jtct.2023.03.001","article-title":"Effect of graft-versus-host disease on post-transplantation outcomes following single cord blood transplantation compared with haploidentical transplantation with post-transplantation cyclophosphamide for adult acute myeloid leukemia","volume":"29","author":"Konuma","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"2025052711320146200_bib10","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.bbmt.2013.02.008","article-title":"Graft-versus-host disease after double-unit cord blood transplantation has unique features and an association with engrafting unit-to-recipient HLA match","volume":"19","author":"Ponce","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2025052711320146200_bib11","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1182\/bloodadvances.2019000836","article-title":"Robust CD4+ T-cell recovery in adults transplanted with cord blood and no antithymocyte globulin","volume":"4","author":"Politikos","year":"2020","journal-title":"Blood Adv"},{"issue":"22","key":"2025052711320146200_bib12","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.1182\/blood-2014-07-589176","article-title":"The role of the thymus in T-cell immune reconstitution after umbilical cord blood transplantation","volume":"124","author":"Politikos","year":"2014","journal-title":"Blood"},{"issue":"3","key":"2025052711320146200_bib13","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.bbmt.2016.11.014","article-title":"Early and long-term impaired T lymphocyte immune reconstitution after cord blood transplantation with antithymocyte globulin","volume":"23","author":"Castillo","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"23","key":"2025052711320146200_bib14","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1182\/blood-2016-06-721936","article-title":"Excellent T-cell reconstitution and survival depend on low ATG exposure after pediatric cord blood transplantation","volume":"128","author":"Admiraal","year":"2016","journal-title":"Blood"},{"issue":"8","key":"2025052711320146200_bib15","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1182\/blood-2014-09-599241","article-title":"Impact of ATG-containing reduced-intensity conditioning after single- or double-unit allogeneic cord blood transplantation","volume":"126","author":"Pascal","year":"2015","journal-title":"Blood"},{"issue":"4","key":"2025052711320146200_bib16","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1182\/blood-2009-01-197178","article-title":"Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versus-host disease","volume":"114","author":"Chen","year":"2009","journal-title":"Blood"},{"issue":"1","key":"2025052711320146200_bib17","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1158\/1078-0432.CCR-10-1198","article-title":"Interleukin-6 modulates graft-versus-host responses after experimental allogeneic bone marrow transplantation","volume":"17","author":"Tawara","year":"2011","journal-title":"Clin Cancer Res"},{"key":"2025052711320146200_bib18","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1186\/s12885-015-1616-z","article-title":"Cytokine serum levels during post-transplant adverse events in 61 pediatric patients after hematopoietic stem cell transplantation","volume":"15","author":"Doring","year":"2015","journal-title":"BMC Cancer"},{"issue":"6","key":"2025052711320146200_bib19","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1038\/sj.leu.2402946","article-title":"Proinflammatory cytokines and their role in the development of major transplant-related complications in the early phase after allogeneic bone marrow transplantation","volume":"17","author":"Schots","year":"2003","journal-title":"Leukemia"},{"issue":"5","key":"2025052711320146200_bib20","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1182\/blood.V98.5.1594","article-title":"Interferon-gamma and interleukin-6 gene polymorphisms associate with graft-versus-host disease in HLA-matched sibling bone marrow transplantation","volume":"98","author":"Cavet","year":"2001","journal-title":"Blood"},{"issue":"12","key":"2025052711320146200_bib21","first-page":"1082","article-title":"IL-6 and IL-8 levels in plasma during hematopoietic progenitor transplantation","volume":"83","author":"Ferra","year":"1998","journal-title":"Haematologica"},{"issue":"2","key":"2025052711320146200_bib22","first-page":"301","article-title":"Serum interleukin-6 levels during bone marrow transplantation: impact on transplant-related toxicity and engraftment","volume":"18","author":"Steffen","year":"1996","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2025052711320146200_bib23","first-page":"85","article-title":"Hyperacute graft-versus-host disease accompanied by increased serum interleukin-6 levels","volume":"60","author":"Imamura","year":"1994","journal-title":"Int J Hematol"},{"issue":"6","key":"2025052711320146200_bib24","first-page":"745","article-title":"Serum cytokine levels in bone marrow transplantation: synergistic interaction of interleukin-6, interferon-gamma, and tumor necrosis factor-alpha in graft-versus-host disease","volume":"13","author":"Imamura","year":"1994","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2025052711320146200_bib25","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/00007890-199209000-00014","article-title":"The relationship of serum IL-6 levels to acute graft-versus-host disease and hepatorenal disease after human bone marrow transplantation","volume":"54","author":"Symington","year":"1992","journal-title":"Transplantation"},{"issue":"13","key":"2025052711320146200_bib26","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S1470-2045(14)71017-4","article-title":"Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1\/2 trial","volume":"15","author":"Kennedy","year":"2014","journal-title":"Lancet Oncol"},{"issue":"4","key":"2025052711320146200_bib27","doi-asserted-by":"crossref","first-page":"717","DOI":"10.3324\/haematol.2017.183434","article-title":"Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft-versus-host disease: low incidence of lower gastrointestinal tract disease","volume":"103","author":"Drobyski","year":"2018","journal-title":"Haematologica"},{"issue":"4","key":"2025052711320146200_bib28","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s00277-020-03968-w","article-title":"IL6-receptor antibody tocilizumab as salvage therapy in severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a retrospective analysis","volume":"99","author":"Kattner","year":"2020","journal-title":"Ann Hematol"},{"issue":"9","key":"2025052711320146200_bib29","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1080\/10428194.2019.1573996","article-title":"Tocilizumab as first-line therapy for steroid-refractory acute graft-versus-host-disease: analysis of a single-center experience","volume":"60","author":"Yucebay","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2025052711320146200_bib30","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41409-018-0236-z","article-title":"Tocilizumab for the treatment of severe steroid-refractory acute graft-versus-host disease of the lower gastrointestinal tract","volume":"54","author":"Ganetsky","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2025052711320146200_bib31","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3109\/10428194.2015.1045896","article-title":"Tocilizumab for steroid refractory acute graft-versus-host disease","volume":"57","author":"Roddy","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"2025052711320146200_bib32","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1016\/j.bbmt.2011.07.001","article-title":"Tocilizumab for the treatment of steroid refractory graft-versus-host disease","volume":"17","author":"Drobyski","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"14","key":"2025052711320146200_bib33","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1182\/blood.2020009050","article-title":"A phase 3 double-blind study of the addition of tocilizumab vs placebo to cyclosporin\/methotrexate GVHD prophylaxis","volume":"137","author":"Kennedy","year":"2021","journal-title":"Blood"},{"issue":"29","key":"2025052711320146200_bib34","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1200\/JCO.2013.53.8157","article-title":"Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation","volume":"32","author":"Sorror","year":"2014","journal-title":"J Clin Oncol"},{"issue":"19","key":"2025052711320146200_bib35","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1182\/blood-2014-03-566216","article-title":"Dominant unit CD34+ cell dose predicts engraftment after double-unit cord blood transplantation and is influenced by bank practice","volume":"124","author":"Purtill","year":"2014","journal-title":"Blood"},{"issue":"8","key":"2025052711320146200_bib36","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1182\/blood-2010-04-280966","article-title":"How I treat: the selection and acquisition of unrelated cord blood grafts","volume":"117","author":"Barker","year":"2011","journal-title":"Blood"},{"issue":"6","key":"2025052711320146200_bib37","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.bbmt.2017.03.006","article-title":"Optimal practices in unrelated donor cord blood transplantation for hematologic malignancies","volume":"23","author":"Barker","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"2025052711320146200_bib38","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.bbmt.2014.01.017","article-title":"Sustained donor engraftment in recipients of double-unit cord blood transplantation is possible despite donor-specific human leukoctye antigen antibodies","volume":"20","author":"Dahi","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"24","key":"2025052711320146200_bib39","doi-asserted-by":"crossref","first-page":"6291","DOI":"10.1182\/bloodadvances.2022008047","article-title":"Extended-duration letermovir prophylaxis for cytomegalovirus infection after cord blood transplantation in adults","volume":"6","author":"Politikos","year":"2022","journal-title":"Blood Adv"},{"issue":"3","key":"2025052711320146200_bib40","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.bbmt.2009.10.022","article-title":"Pre-engraftment syndrome after double-unit cord blood transplantation: a distinct syndrome not associated with acute graft-versus-host disease","volume":"16","author":"Patel","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"2025052711320146200_bib41","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"issue":"4","key":"2025052711320146200_bib42","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1046\/j.1365-2141.1997.1112925.x","article-title":"IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade","volume":"97","author":"Rowlings","year":"1997","journal-title":"Br J Haematol"},{"issue":"3","key":"2025052711320146200_bib43","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"2025052711320146200_bib44","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.bbmt.2007.08.047","article-title":"A scheme for defining cause of death and its application in the T cell depletion trial","volume":"13","author":"Copelan","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"2025052711320146200_bib45","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/j.cell.2023.05.007","article-title":"High-resolution analyses of associations between medications, microbiome, and mortality in cancer patients","volume":"186","author":"Nguyen","year":"2023","journal-title":"Cell"},{"issue":"1","key":"2025052711320146200_bib46","doi-asserted-by":"crossref","first-page":"250","DOI":"10.3324\/haematol.2022.281309","article-title":"Mitigation of gastrointestinal graft-versus-host disease with tocilizumab prophylaxis is accompanied by preservation of microbial diversity and attenuation of enterococcal domination","volume":"108","author":"Chhabra","year":"2023","journal-title":"Haematologica"},{"issue":"22","key":"2025052711320146200_bib47","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1182\/blood.2021015352","article-title":"Preservation of the fecal microbiome is associated with reduced severity of graft-versus-host disease","volume":"140","author":"Burgos da Silva","year":"2022","journal-title":"Blood"},{"issue":"23","key":"2025052711320146200_bib48","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1182\/blood.2019000396","article-title":"IL-6 dysregulation originates in dendritic cells and mediates graft-versus-host disease via classical signaling","volume":"134","author":"Wilkinson","year":"2019","journal-title":"Blood"},{"issue":"7","key":"2025052711320146200_bib49","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/bmt.2012.279","article-title":"Pre-engraftment syndrome after myeloablative dual umbilical cord blood transplantation: risk factors and response to treatment","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2025052711320146200_bib50","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1600-0609.2011.01709.x","article-title":"Pre-engraftment syndrome after unrelated donor umbilical cord blood transplantation in patients with hematologic malignancies","volume":"88","author":"Wang","year":"2012","journal-title":"Eur J Haematol"},{"issue":"11","key":"2025052711320146200_bib51","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/j.bbmt.2017.07.020","article-title":"Cytokine profiles of pre-engraftment syndrome after single-unit cord blood transplantation for adult Patients","volume":"23","author":"Konuma","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2025052711320146200_bib52","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.1038\/s41467-021-24412-1","article-title":"Inflammatory monocytes promote pre-engraftment syndrome and tocilizumab can therapeutically limit pathology in patients","volume":"12","author":"Jin","year":"2021","journal-title":"Nat Commun"},{"issue":"10","key":"2025052711320146200_bib53","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/j.bbmt.2016.06.010","article-title":"Severe cytokine-release syndrome after T cell-replete peripheral blood haploidentical donor transplantation is associated with poor survival and anti-IL-6 therapy is safe and well tolerated","volume":"22","author":"Abboud","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"2025052711320146200_bib54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jim.2016.03.005","article-title":"Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and\/or siltuximab following CAR T cell therapy","volume":"434","author":"Chen","year":"2016","journal-title":"J Immunol Methods"},{"issue":"6","key":"2025052711320146200_bib55","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.bbmt.2019.02.007","article-title":"Development of pre-engraftment syndrome, but not acute graft-versus-host disease, reduces relapse rate of acute myelogenous leukemia after single cord blood transplantation","volume":"25","author":"Isobe","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2025052711320146200_bib56","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1182\/blood.V73.3.666.666","article-title":"Human interleukin-6 supports granulocytic differentiation of hematopoietic progenitor cells and acts synergistically with GM-CSF","volume":"73","author":"Caracciolo","year":"1989","journal-title":"Blood"},{"issue":"3","key":"2025052711320146200_bib57","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1182\/blood.V77.3.472.472","article-title":"Administration of interleukin-6 stimulates multilineage hematopoiesis and accelerates recovery from radiation-induced hematopoietic depression","volume":"77","author":"Patchen","year":"1991","journal-title":"Blood"},{"issue":"3","key":"2025052711320146200_bib58","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1182\/blood.V80.3.688.688","article-title":"Recombinant glycosylated human interleukin-6 accelerates peripheral blood platelet count recovery in radiation-induced bone marrow depression in baboons","volume":"80","author":"Herodin","year":"1992","journal-title":"Blood"},{"issue":"6","key":"2025052711320146200_bib59","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1182\/blood.V83.6.1690.1690","article-title":"Potential use of interleukin-6 in bone marrow transplantation: effects of recombinant human interleukin-6 after syngeneic and semiallogeneic bone marrow transplantation in mice","volume":"83","author":"Givon","year":"1994","journal-title":"Blood"},{"issue":"6469","key":"2025052711320146200_bib60","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1126\/science.aax3760","article-title":"Lactose drives Enterococcus expansion to promote graft-versus-host disease","volume":"366","author":"Stein-Thoeringer","year":"2019","journal-title":"Science"},{"issue":"9","key":"2025052711320146200_bib61","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1056\/NEJMoa1900623","article-title":"Microbiota as predictor of mortality in allogeneic hematopoietic-cell transplantation","volume":"382","author":"Peled","year":"2020","journal-title":"N Engl J Med"},{"issue":"11","key":"2025052711320146200_bib62","doi-asserted-by":"crossref","first-page":"e4627","DOI":"10.1093\/cid\/ciaa068","article-title":"Compositional flux within the intestinal microbiota and risk for bloodstream infection with gram-negative bacteria","volume":"73","author":"Stoma","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"7","key":"2025052711320146200_bib63","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jtct.2021.03.012","article-title":"Guidelines for the prevention and management of graft-versus-host disease after cord blood transplantation","volume":"27","author":"Ponce","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"2025052711320146200_bib64","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jtct.2020.11.008","article-title":"Guidelines for adult patient selection and conditioning regimens in cord blood transplant recipients with hematologic malignancies and aplastic anemia","volume":"27","author":"Metheny","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"10","key":"2025052711320146200_bib65","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1016\/j.bbmt.2020.06.018","article-title":"Guidelines for cord blood unit thaw and infusion","volume":"26","author":"Scaradavou","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"2025052711320146200_bib66","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1016\/j.bbmt.2020.07.030","article-title":"Guidelines for cord blood unit selection","volume":"26","author":"Politikos","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"2025052711320146200_bib67","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.jtct.2021.01.024","article-title":"Guidelines for infection prophylaxis, monitoring and therapy in cord blood transplantation","volume":"27","author":"Olson","year":"2021","journal-title":"Transplant Cell Ther"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/10\/2570\/2376699\/blooda_adv-2024-014177-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/10\/2570\/2376699\/blooda_adv-2024-014177-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T15:32:19Z","timestamp":1748359939000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/10\/2570\/534833\/Phase-2-trial-of-cyclosporine-A-mycophenolate"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,27]]},"references-count":67,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,5,27]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024014177","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5,27]]},"published":{"date-parts":[[2025,5,27]]}}}